Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma

Despite the advances in screening protocols and treatment options, hepatocellular carcinoma (HCC) is still considered to be the most lethal malignancy in patients with liver cirrhosis. Moreover, the survival outcomes after failure of first-line therapy for unresectable HCC is still poor with limited...

Full description

Bibliographic Details
Published in:	Vaccines
Main Authors:	Mohamed A. Abd El Aziz, Antonio Facciorusso, Tarek Nayfeh, Samer Saadi, Mohamed Elnaggar, Christian Cotsoglou, Rodolfo Sacco
Format:	Article
Language:	English
Published:	MDPI AG 2020-10-01
Subjects:	HCC CPI immunotherapy survival progression
Online Access:	https://www.mdpi.com/2076-393X/8/4/616

Similar Items

Angiotensin Receptor 1 Blockers Prolong Time to Recurrence after Radiofrequency Ablation in Hepatocellular Carcinoma patients: A Retrospective Study
by: Antonio Facciorusso, et al.
Published: (2020-10-01)

Combination of alpha-fetoprotein and neutrophil-to-lymphocyte ratio to predict treatment response and survival outcomes of patients with unresectable hepatocellular carcinoma treated with immune checkpoint inhibitors
by: Hong-Fei Zhu, et al.
Published: (2023-06-01)

Efficacy of atezolizumab plus bevacizumab for unresectable HCC: Systematic review and meta-analysis of real-world evidence
by: Giulia Francesca Manfredi, et al.
Published: (2025-08-01)

Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: An Overview
by: Diederick J. van Doorn, et al.
Published: (2020-12-01)

Nomograms confirm serum IL-6 and CRP as predictors of immune checkpoint inhibitor efficacy in unresectable hepatocellular carcinoma
by: Jiajia Du, et al.
Published: (2024-01-01)

NLR stability predicts response to immune checkpoint inhibitors in advanced hepatocellular carcinoma
by: Jiajia Du, et al.
Published: (2024-08-01)

Biomarkers predicting the efficacy of immune checkpoint inhibitors in hepatocellular carcinoma
by: Ran Qin, et al.
Published: (2023-12-01)

The pattern of tumor progression on first-line immune checkpoint inhibitor-based systemic therapy for Chinese advanced hepatocellular carcinoma –CLEAP 004 study
by: Chao-Xu Yang, et al.
Published: (2024-04-01)

Hepatocellular Carcinoma: A Review
by: Tarana Gupta
Published: (2020-09-01)

Neoadjuvant Immune Checkpoint Inhibitors in hepatocellular carcinoma: a meta-analysis and systematic review
by: Chunhong Tian, et al.
Published: (2024-02-01)

Efficacy and factors related to prognosis of combination chemotherapy with different radiotherapy methods in patients with unresectable hepatocellular carcinoma
by: Lian-Qiang Han
Published: (2025-04-01)

Prediction of prognosis of immune checkpoint inhibitors combined with anti-angiogenic agents for unresectable hepatocellular carcinoma by machine learning-based radiomics
by: Xuni Xu, et al.
Published: (2025-05-01)

Identification of prognostic factors and nomogram model for patients with advanced lung cancer receiving immune checkpoint inhibitors
by: Xiuqiong Chen, et al.
Published: (2022-12-01)

Safety and clinical efficacy of immune checkpoint inhibitors in pediatric hepatocellular carcinoma: a case report and review of the literature
by: Xiaoting Zhong, et al.
Published: (2025-08-01)

Efficacy and safety of immune checkpoint inhibitors for EGFR mutated non-small cell lung cancer: a network meta-analysis
by: Lin Zhu, et al.
Published: (2024-12-01)

Current Evidence for Immune Checkpoint Inhibition in Advanced Hepatocellular Carcinoma
by: Victoria Foy, et al.
Published: (2023-09-01)

Predicting the outcome of transarterial chemoembolization combined with targeted immunotherapy for unresectable hepatocellular carcinoma based on MRI radiomics
by: Jiaxuan Liu, et al.
Published: (2025-10-01)

Liver Injury and Its Impact on Prognosis in Patients with HBV-Related Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization Combined with Tyrosine Kinase Inhibitors Plus Immune Checkpoint Inhibitors
by: Shen J, et al.
Published: (2024-01-01)

The Role of Timing of Progression and Early Salvage Surgery in Unresectable Hepatocellular Carcinoma Treated with TACE Plus TKIs and PD‑1 Inhibitors
by: Li X, et al.
Published: (2024-08-01)

Prognostic value of preoperative prealbumin levels in patients with unresectable hepatocellular carcinoma undergoing transcatheter arterial chemoembolisation
by: Kai Lei, et al.
Published: (2023-08-01)

Lipid nanoparticles that deliver IL-12 messenger RNA suppress tumorigenesis in MYC oncogene-driven hepatocellular carcinoma
by: Ian Lai, et al.
Published: (2018-11-01)

Gut Microbiome Modulation in Hepatocellular Carcinoma: Preventive Role in NAFLD/NASH Progression and Potential Applications in Immunotherapy-Based Strategies
by: Elisa Monti, et al.
Published: (2025-01-01)

CA19-9-related macrophage polarization drives poor prognosis in HCC after immune checkpoint inhibitor treatment
by: Tingting Du, et al.
Published: (2025-01-01)

Analisis Indeks Harga Konsumen (IHK) Menurut Kelompok Pengeluaran Nasional Tahun 2018
by: Halida Sofiah Noor, et al.
Published: (2019-12-01)

Current Strategies for Modulating Tumor-Associated Macrophages with Biomaterials in Hepatocellular Carcinoma
by: Qiaoyun Liu, et al.
Published: (2023-02-01)

Clinical and molecular implications of cGAS/STING signaling in checkpoint inhibitor immunotherapy
by: Hao Chen, et al.
Published: (2025-05-01)

Early Alpha-Fetoprotein Response Predicts Sustained Tumor Response Following Immune Checkpoint Inhibitors Combined with Targeted Therapy in Liver Cancer
by: Jiahe Tian, et al.
Published: (2024-12-01)

The Role of Immune Checkpoint Blockade in the Hepatocellular Carcinoma: A Review of Clinical Trials
by: Muhammet Ozer, et al.
Published: (2021-12-01)

Efficacy and safety of molecularly targeted agents and immune checkpoint inhibitors for unresectable or recurrent/metastatic oral cancer in Japan
by: Mitsunobu Otsuru, et al.
Published: (2024-07-01)

Identification of four prognostic LncRNAs for survival prediction of patients with hepatocellular carcinoma
by: Zhonghao Wang, et al.
Published: (2017-07-01)

Ultrasound-triggered nano delivery of lenvatinib for selective immunotherapy treatment against hepatocellular carcinoma
by: Lu Sun, et al.
Published: (2024-11-01)

Development of a prognostic scoring model for predicting the survival of elderly patients with hepatocellular carcinoma
by: Sizhe Wan, et al.
Published: (2020-02-01)

Characteristics and outcomes of primary and secondary resistance to immune checkpoint inhibitors in hepatocellular carcinoma
by: Xiaowen Cui, et al.
Published: (2025-06-01)

Comprehensive Analysis of Angiogenesis and Ferroptosis Genes for Predicting the Survival Outcome and Immunotherapy Response of Hepatocellular Carcinoma
by: Wang P, et al.
Published: (2024-09-01)

A Comprehensive Insight and In Silico Analysis of CircRNAs in Hepatocellular Carcinoma: A Step toward ncRNA-Based Precision Medicine
by: Rana A. Youness, et al.
Published: (2024-07-01)

Immune checkpoint inhibitors for unresectable malignant pleural mesothelioma
by: Giulio Metro, et al.
Published: (2021-09-01)

Emerging Role of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma
by: Vito Longo, et al.
Published: (2019-10-01)

Treatment of Donor Cells with Oxidative Phosphorylation Inhibitor CPI Enhances Porcine Cloned Embryo Development
by: Jinping Cao, et al.
Published: (2024-04-01)

Epigenetic modification-related mechanisms of hepatocellular carcinoma resistance to immune checkpoint inhibition
by: Shengwei Tao, et al.
Published: (2023-01-01)

Statin therapy: a potential adjuvant to immunotherapies in hepatocellular carcinoma
by: Jiao Wang, et al.
Published: (2024-02-01)